Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed
Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial
Practical Guidance for Drinking on GLP-1 Medications If you decide to drink alcohol while taking semaglutide or tirzepatide, strategies exist to minimize risks and side effects
Members can access CloseKnit through MyAccount or information is provided on www.carefirst.com/fcps
US$ 29.04
US$ 28.58
US$ 28.78
